Background. Point-of-care tests (POCT) can assist general practitioners (GPs) in diagnosing and treating patients with acute cardiopulmonary symptoms, but it is currently unknown if POCT impact relevant clinical outcomes in these patients. Objective. To assess whether using POCT in primary care patients with acute cardiopulmonary symptoms leads to more accurate diagnosis and impacts clinical management. Methods. We performed a systematic review in four bibliographic databases. Articles published before February 2016 were screened by two reviewers. Studies evaluating the effect of GP use of POCT on clinical diagnostic accuracy and/or effect on treatment and referral rate in patients with cardiopulmonary symptoms were included. Results. Our search yielded nine papers describing data from seven studies, on the clinical diagnostic accuracy of POCT in a total of 2277 primary care patients with acute cardiopulmonary symptoms. Four papers showed data on GP use of D-dimer POCT in pulmonary embolism (two studies); two studies on Troponin T in acute coronary syndrome; one on heart-type fatty acidbinding protein (H-FABP) in acute coronary syndrome; one on B-type natriuretic peptide (BNP) in heart failure; one on 3-in-1 POCT (Troponin T, BNP, D-dimer) in acute coronary syndrome, heart failure and/or pulmonary embolism. Only one study assessed the effect of GP use of POCT on treatment initiation and one on actual referral rates. Conclusion. There is currently limited and inconclusive evidence that actual GP use of POCT in primary care patients with acute cardiopulmonary symptoms leads to more accurate diagnosis and affects clinical management. However, some studies show promising results, especially when a POCT is combined with a clinical decision rule.
Introduction
Excluding serious conditions is one of the cornerstones of general practice consultations. General practitioners (GPs) often use diagnostic tests to assist their decision-making process (1) . A wide range of point-of-care tests (POCT) is currently available to GPs, but at present only few POCT are widely used by GPs (2) . GPs across countries have expressed a desire to use more POCT in their practice, especially to help them diagnose acute conditions like acute thromboembolic conditions (D-dimers), and heart diseases (Troponin, B-type natriuretic peptide) (2) . This is understandable as patients with cardiopulmonary symptoms are often diagnostically challenging for GPs. POCT could assist GPs in diagnosing and treating patients with these symptoms, but GPs have expressed reservations towards using additional POCT as well, including doubts about the reliability of these tests (3) . Nonetheless, several studies have shown that the use of POCT may reduce referrals to secondary care or drug prescriptions, and lead to higher patient satisfaction and better adherence to treatment (4) (5) (6) (7) . GPs generally consider the effectiveness of use of a POCT on the decision-making process as the most important aspect in their consideration to use a POCT (8) .
Before advocating a widespread use and implementation of GP use of POCT in patients with acute cardiopulmonary symptoms, it is important to determine if GP use of these tests actually affects clinical outcomes of patients. Therefore, the aim of this systematic review is to assess whether using POCT in primary care leads to more accurate diagnosis and impacts clinical management in patients with acute cardiopulmonary symptoms.
Method

Search strategy
We performed a systematic electronic literature search in four bibliographic databases: PubMed, EMBASE, CINAHL and the Cochrane library. All articles published before October 2014 were included. We searched the databases for articles on (acute) cardiopulmonary disease and point-of-care testing in primary care. We included several free search terms per category as well as MESH terms. The exact search terms for the PubMed search are shown in Box 1. No search limits were applied. We performed a PubMed search update from October 2014 till February 2016. Furthermore, we checked the reference lists of all included articles for other relevant studies. When no full texts were available, e.g. in the case of conference abstracts, we contacted the authors to retrieve a full manuscript when available.
Study selection
After removing duplicates, two reviewers (JS, AS and in search update AS, JC) independently screened titles and abstracts for predefined PICOS criteria on population and intervention (Box 2). In case of disagreement, a third reviewer (JC) independently screened title and abstract and the record was discussed in a consensus meeting. Subsequently, one reviewer (JC) screened and another reviewer (AS) checked the full-texts of the remaining records on all PICOS criteria.
All PICOS criteria were predefined in a study protocol and were defined in more detail during the review process. We excluded all studies that did not agree with the PICOS criteria. During this stage, we decided to also exclude papers on the use of POCT in (acute respiratory)infections, as many articles, including systematic reviews, have been published on this topic (9) (10) (11) .
Data extraction and analysis
Data extraction was performed by one reviewer (AS) and the extracted results were studied by all authors. When diagnostic accuracy outcomes were not presented in the article, we calculated them when possible. The heterogeneity among studies precluded a meta-analysis. Therefore, we undertook a narrative synthesis of the data to explore the evidence for the clinical effectiveness of GP use of POCT in primary care patients with cardiopulmonary symptoms.
Quality assessment
The internal and external validity of the two trails was assessed using the Cochrane Risk of Bias Tool for randomized trails (12) . Furthermore, the risk of bias for the diagnostic accuracy outcomes in all studies, was assessed using the QUADAS-2 tool (13). All assessments were performed by one reviewer (AS) and checked for accuracy by a second (JC). Quality criteria for inclusion were not set as we intended to be broad-based and only few studies were included on the basis of eligibility.
Results
Study selection and study characteristics
From 3657 records, we identified 3079 unique records; 3078 from the database searches and one additional record through a conference abstract. We assessed 169 full-text articles for eligibility and nine papers met our inclusion criteria (Figure 1 ) (14) (15) (16) (17) (18) (19) (20) (21) (22) . Eight of nine papers were published within the past 5 years. Study characteristics of the included papers and accuracy outcomes are shown in Tables 1 and 2 . All studies were prospective and two were randomized trials. The included studies all had domains with high risk of bias using the Cochrane Risk of Bias Tool for both trails and the ((((((((((((point of (((((((((((((((((((((cardiopulmonary (Tables  3 and 4 ). Main risks of bias for the diagnostic accuracy outcomes were not all patients receiving the same reference standard and some patients were only followed-up without any extra tests done to confirm absence of the index disease.
Clinical diagnostic accuracy
The eligible nine papers described data of seven different studies which showed relevant data on the clinical diagnostic accuracy of GP use of POCT in patients with acute cardiopulmonary symptoms in primary care (Tables 1 and 2 ). Three papers described the results of one large clinical study (AMUSE-2) evaluating the effect of D-Dimer POCT for pulmonary embolism (14) (15) (16) . We found one additional study on D-dimer POCT. Hence, four papers showed data on GP use of D-dimer POCT, two studies on GP use of Troponin T, one on GP use of heart-type fatty acid-binding protein (H-FABP), one on GP use of B-type natriuretic peptide (BNP) and one on a 3-in-1 POCT (Troponin T, BNP, D-dimer) (14) (15) (16) (17) (18) (19) (20) (21) (22) .
Pulmonary embolism
In a prospective cohort study, Geersing et al. (14) investigated the diagnostic value of a combination of the Wells clinical decision rule and a D-dimer POCT to safely exclude pulmonary embolism in 598 adult patients clinically suspected of pulmonary embolism. Seventythree (12%) patients were diagnosed with a pulmonary embolism. This study concluded that pulmonary embolism can be safely and efficiently excluded on the basis of a Wells score of ≤4 combined with a negative D-dimer POCT result, with a positive and negative predictive value (PPV and NPV) of 21.2 and 98.5%, respectively. Using a Wells threshold of <2 was even safer, but this was at the expense of the specificity (Table 2) (14) . In a post hoc analysis by Lucassen et al. (15) , the D-dimer POCT had a higher specificity as a stand-alone POCT compared to the combination of a D-dimer POCT with the Wells, yet it was less safe with a NPV of 96%. A subanalysis of the same study population by Erkens et al. (16) showed that a positive Wells rule or a positive D-dimer POCT are not only positively associated with pulmonary embolism, but also with other clinically relevant diseases, for example pneumonia. In another prospective cohort study by Schouten et al. (17) , wherein 150 patients were entered via the AMUSE-2 study, a NPV of 94% was found when using a combination of the Wells rule (≤4 points) and a D-dimer POCT in 294 elderly ambulatory adults (≥60 years) suspected of having a pulmonary embolism. The NPV and the specificity in this study was considerately lower than in the study from Geersing et al. (14) when compared with the same Wells cut-off score. The NPV was also lower when compared to the Wells <2 condition in the study by Geersing and compared to the D-dimer as a stand-alone test by Lucassen. A scenario analyses in the study of Schouten showed that lowering the threshold for the Wells rule did not improve the failure rate (6.3%) (17) . The percentage of patients diagnosed with a pulmonary embolism was higher-and the included patients were older-in the study by Schouten (28%) compared to Geersing et al. (14) 
(12%).
Acute coronary syndrome and heart failure Two prospective cohort studies by Planer et al. (18) and Nilsson et al. (19) investigated the diagnostic value of Troponin T in patients with chest pain or other symptoms clinically suggestive of acute coronary syndrome. Planer studied the diagnostic value of Troponin T POCT for the diagnosis of acute myocardial infarction in 349 patients (>30 years) with at least 20 min consecutive chest pain beginning at least 8 h prior to presentation and occurring within the previous 6 days. Of all 349 patients, only 6 (1.7%) were diagnosed with a myocardial infarction, of which one was missed by the Troponin T POCT. They calculated a sensitivity of 83% and a specificity of 100% for a diagnosis of myocardial infarction within 72 h. The PPV and NPV were 100 and 99.7%, respectively. The sensitivity, specificity, PPV and NPV all increased to 100% when the test was combined with the family physician's clinical decision. They concluded that Troponin T POCT had a very high diagnostic value for the evaluation of patients with non-recent onset chest pain in family practice (18) .
The results of Nilsson were less positive with regards to the sensitivity and PPV of Troponin T POCT. This prospective cohort study investigated the diagnostic value of GP use of Troponin T POCT in 196 patients (≥35 years) with chest pain, dyspnoea on exertion, unexplained weakness and/or fatigue commenced or worsened during the last 7 days. Of all patients, 128 patients were diagnosed by GPs using a Troponin T POCT. Within the intervention group only 3 (2.3%) patients were diagnosed with a myocardial infarction and 4 (3.1%) with unstable angina. All patients with an unstable angina had a false negative Troponin T POCT, which was also the case in the study by Planer. They calculated a sensitivity of 67%, a specificity of 98%, PPV of 40% and NPV of 99% for acute myocardial infarction among patients with chest pain. When adding unstable angina to the outcome group, both the sensitivity and NPV decreased to 29 and 96%, respectively (19) .
Box 2. PICOS criteria Population
Patients with acute cardiopulmonary conditions/symptoms in primary care in Western/developed countries. Acute cardiopulmonary was defined as acute conditions or symptoms of either the heart, lungs or vascular blood supply of these organs at the height of the chest cavity. For example, we excluded studies on non-chest related conditions like deep venous thrombosis or upper respiratory tract infection. Furthermore, we excluded studies on fairly uncommon diseases in Western countries, e.g. tuberculosis and HIV.
Intervention
All studies that reported on POCT as an intervention. POCT was defined as biomedical tests on patient material, e.g. blood, urine, faeces, performed and analysed at the point-of-care. We excluded tests like electrocardiography, ultrasonography and spirometry.
Comparator
Care as usual; no use of a POCT.
Outcomes
We included studies on clinical effectiveness; clinical diagnostic accuracy and/or effect on treatment and referral rates. We excluded studies on analytical test accuracy or studies with the objective to determine the optimal cut-off value for a POCT.
Study design
Randomized controlled trails and non-randomized controlled trails, e.g. prospective cohort studies.
Bruins Slot et al. (20) investigated the diagnostic accuracy of H-FABP POCT in 298 patients-with symptoms less than 24 hsuspected of acute coronary syndrome in a prospective cohort study in primary care. In this study substantially more patients were diagnosed with an acute coronary syndrome, 66 of 298 (22%) to be exact, of which 14 (21%) with unstable angina, and 52 (79%) with myocardial infarction, compared to the study population of Planer and Nilsson. By adding H-FABP POCT to the regular diagnostic model for acute coronary syndrome, the area under the receiver operating curve increased from 0.66 to 0.75. The sensitivity, specificity, PPV and NPV of H-FABP were 43, 94, 72 and 83%, respectively, when symptoms occurred no longer than 6 h and 39, 94, 65 and 84%, respectively, when symptoms occurred no longer than 24 h (20).
Burri et al. (21) investigated the diagnostic accuracy of BNPguided diagnosis for heart failure in 323 adult patients presenting with new onset or clearly worsening dyspnoea as their primary symptom in an individually randomized controlled trail. Heart failure was diagnosed in 111 (34%) patients. The BNP-guided diagnostic strategy compared to standard management increased diagnostic accuracy from 33 to 45%. The area under the receiver operating curve for BNP to identify heart failure was 0.87. At the optimal cutoff of 153 ng/l, the sensitivity, specificity, PPV and NPV were 72, 93, 88 and 84%, respectively (21) .
Pulmonary embolism, acute coronary syndromes and heart failure In a multicentre cluster-randomized controlled trial, Tomonaga et al. (22) studied the clinical benefit of a 3-in-1 POCT with Troponin T, BNP and D-dimer, compared to conventional diagnosis in 369 patients with potentially cardiovascular chest pain or symptoms. An acute coronary syndrome was diagnosed in 33 (8.9%) patients, heart failure in 51 (13.8%) patients and a thromboembolic event in 24 (6.5%) patients. The diagnoses of acute coronary syndromes, heart failure and thromboembolic events were significantly more correct in the POCT group, with 69.8% correct diagnoses in the POCT group compared to 45.2% in the standard care group. The sensitivity, specificity, PPV and NPV of Troponin T POCT for acute coronary syndrome were 59, 93, 53 and 95%, respectively. GP use of BNP POCT for heart failure had a sensitivity, specificity, PPV, and NPV of 100, 72, 74 and 100% respectively and GP use of D-dimer POCT for thromboembolic conditions 93, 78, 36 and 99%, respectively (22) .
Clinical management
Hardly any studies evaluated the actual clinical management when using POCT. With regards to treatment, Burri et al. did evaluate the time to appropriate treatment, comparing the intervention group that used a BNP POCT to the control group. GP use of a BNP POCT significantly reduced the time to initiation of appropriate treatment by 12 days. In 66% of patients appropriate treatment was initiated on the day of initial presentation in the BNP POCT group, compared with 53% in the control group.
Only one study evaluated the effect of GP use of a POCT on actual referral rates to secondary care. The Nilsson study had emergency referrals within 30 days of study enrolment as primary outcome. Patients managed by physicians using Troponin T POCT were referred in 25% of cases compared to 43% of patients managed by physicians without POCT. However, two patients who were not referred in the Troponin T POCT group were judged as missed cases, with one having an acute myocardial infarction and one unstable angina. Therefore, Nilsson et al concluded that the use of Troponin T POCT in patients with chest pain including those with acute chest pain may reduce emergency referrals, but probably at the cost of an increased risk to miss patients with an acute myocardial infarction or unstable angina (19) . In all of the other included studies actual referral rates were not determined, although some studies-including those on D-dimer POCT-tried to estimate the number of avoidable referrals to secondary care through scenario analyses.
Discussion
Summary
Only few prospective studies evaluating the effect of GP use of POCT on clinical diagnostic accuracy and clinical management in primary care patients with cardiopulmonary symptoms have been performed. All studies were considered at high risk of bias. As such, we currently have insufficient and inconclusive evidence to conclude that GP use of POCT in primary care patients with acute cardiopulmonary symptoms leads to more accurate diagnosis and impacts clinical management. Evidence from a large prospective study on GP use of D-dimer POCT suggests more accurate diagnosis when combining the use of a POCT with a clinical decision rule. As expected, heterogeneity among studies was high and therefore we were unable to perform a meta-analysis.
Strengths and limitations
This is the first systematic review on the clinical effectiveness of GP use of POCT in primary care patients with acute cardiopulmonary symptoms. We specifically chose to focus on a broad range of cardiopulmonary symptoms and not one specific condition or biomarker, as typical patients in general practice present with symptoms and not diagnoses. Making an accurate clinical decision within a 10-15-min consultation is part of the complexity of general practice. We therefore chose to perform a broad search to not miss any potential studies. We specifically excluded studies performed in secondary care, including those performed at A&E departments, to minimize the risk for spectrum bias. Spectrum bias describes the effect a change in patient case mix may have on the performance of a test (23) .
There are several potential limitations of this review. Although we carefully predefined POCT, PICOS criteria and exclusion criteria at the start of the study, some studies were difficult to assess for eligibility because of differences in terminology. Therefore, all records were screened by at least two reviewers and in case of doubt were discussed in a consensus meeting. As all eligible papers of the initial search in four databases were present in PubMed, we decided to only perform the search update in Pubmed.
Comparison with existing literature
The sensitivity and specificity of GP use of D-dimer POCT as a stand-alone test in a primary care population suspected of pulmonary embolism as shown by Lucassen is comparable to the sensitivity of 82.6% and specificity of 60.5% found in a prospective observational study by Runyon et al. (24) in a low risk emergency department population of 1193 patients evaluated for pulmonary embolism. However, the NPV was somewhat higher in the low risk emergency department population, i.e. 99.4% (15, 24) . Knudsen et al. (25) evaluated the accuracy of BNP testing for the diagnosis of heart failure in an unselected group of 155 patients with acute dyspnoea in an emergency department setting and found a comparable area under the receiver operating curve for BNP compared to the findings of Burri, ranging between 0.82 and 0.90 depending on age and gender. Two systematic reviews by Bruins Slot et al. concluded that H-FABP POCT at a cut-off value of 6.2 or 7 ng/ml does not fulfil the requirements for safe and early diagnosis of acute myocardial infarction in a hospital and pre-hospital setting when used as a stand-alone test (26, 27) . This is in line with the conclusion of the primary care study by Bruins Slot et al. (20) . With regards to the clinical value of Troponin POCT in a secondary care population, the literature is inconclusive, which is consistent with the findings of the primary care studies (27) .
Implications for research and practice
Limited research has been done with regards to cardiopulmonary POCT in primary care clinical practice. Current clinical research mainly evaluates accuracy of POCT and diagnostic yield, when considering the test-treatment pathway. Only a few studies (also) report on clinical management outcomes, e.g. Nilsson evaluated referral rates to secondary care and Burri evaluated timing of treatment (28) . There are several factors that currently hamper the comparison of outcomes of these studies, including different devices, biomarkers and diseases, study populations and study size, cut-off values and (combinations with) clinical decision rules.
Acute cardiopulmonary conditions can have serious clinical consequences and so excluding serious pathology is one of the key objectives of GPs when managing these patients. Therefore, if GP use of a specific POCT is to be advocated, the NPV of that POCT is of major importance. Some POCT may have a high NPV in a secondary care population, but a lower and insufficient NPV in primary care.
For that reason, we should not assume that the outcomes of POCT studies in secondary care are automatically applicable to primary care, as previously discussed in terms of spectrum bias (23) . Also (17) ?
, low risk of bias; , high risk of bias; ?, unclear risk of bias.
a There were no concerns regarding applicability in any of these studies. within primary care, differences in study population could have a major influence on the usefulness of a POCT, as a small difference in test characteristics might render the use of a cardiopulmonary POCT unsafe in certain populations. Therefore, it is very important to define, in a clinical decision pathway, for which patients the POCT is tested effective and safely applicable. One should be careful when determining the NPV for a primary care population wherein the incidence of a certain disease is low, because when the study population is of insufficient size the test characteristics cannot be calculated reliably. Nilsson and Planer did calculate the NPV value even with only very few patients having a myocardial infarction. This may have led to an overestimation of the NPV of a Troponin T POCT for myocardial infarction in their study population. It is also important to notice that all patients with an unstable angina in the studies of Nilsson and Planer had a negative Troponin T POCT. By definition, the diagnosis of unstable angina is based on unstable cardiac ischemic symptoms without a rise in biomarkers and therefore in essence no biomarkers should be detectable. On the other hand, the incidence of unstable angina is decreasing as patients diagnosed with unstable angina in the past are now being diagnosed with myocardial infarction due to the lower detection thresholds of modern biomarker tests, e.g. high-sensitive Troponin tests. This illustrates the need for modern POCT to gain equal sensitivity to high-sensitive laboratory tests (29) .
The chosen cut-off values have also proven to be important when evaluating POCT. Not all studies use the same cut-off values, which influences test characteristics and study outcomes and it makes comparison among study outcomes difficult. For several biomarkers there is an ongoing debate on the optimal cut-off value. For example, it is suggested that the best NT-proBNP cut-off point to exclude heart failure in an ambulatory population is 280 pg/ml, which showed an area under the ROC curve of 0.94. This same study compared that cut-off value with recommended diagnostic cut-off values applied to their population, which ranged from 50 pg/ml in patients younger than 50 years to 400 pg/ml (NICE guidelines) (30, 31) . The study by Burri only reported the test characteristic when using the optimal cut-off value (153 pg/ml) for their study population. Not predefining the test threshold, but selecting the optimal cut-off for the study population to optimize test characteristics may lead to an overestimation of test performance, as the test performance of the same POCT in another independent sample of patients is likely to be inferior (32) . A similar discussion on the optimal cut-off value can be held for D-dimer POCT in elderly patients, which some believe should be higher than 500 ng/ml (33) . The cut-off value for the qualitative D-dimer POCT in the study by Geersing was even lower than 500 ng/ml, to be exact 80 ng/ml. Lower cut-off values for H-FABP and Troponin-when available as POCT-can increase safety by decreasing false negative results (34) . Differences in cut-off points also play a role in clinical decisions rules, for example the Wells clinical decision rule. Using a Wells cut-off score of <2 is safer in the exclusion of pulmonary embolism than a score of ≤4, but at the cost of a lower efficiency and specificity (14) .
Another factor that complicates comparison among studies is that clinical diagnostic accuracy of a POCT is sometimes presented as a stand-alone test and sometimes combined with a clinical decision rule. With regards to the diagnosis of pulmonary embolism a validated and frequently used clinical decision rule in primary care exists, i.e. the Wells rule, which when combined with the D-dimer POCT has a lower failure rate than the D-dimer POCT as a stand-alone test (14, 15, 35, 36) . Such a frequently used and integrated clinical decision rule for the diagnosis of coronary heart disease in primary care does not exist yet. The HEART score for example was developed for patients in an emergency department setting and is not as easily applicable to primary care (37) (38) (39) . The Marburg Heart Score (MHS), however, may be useful in the initial triage of patients suspected of coronary heart disease in general practice (40) (41) (42) . Nonetheless, as of yet this clinical decision rule is not commonly used. If a validated cardiac clinical decision rule like the MHS would be added to a Troponin POCT, this would most likely lead to a more effective and safer exclusion of acute cardiac pathology. More research is necessary to investigate whether the combination of the two leads to a high enough NPV to safely exclude cardiac pathology.
Several factors should be taken into consideration when implementing POCT in practice (43) . Lack of evidence could lead to limited trust in a POCT, which in turn could lead to referral to secondary care regardless of the test result. If a POCT were to be implemented, physicians should be aware of the risk of non-evidence based testing for other conditions, but also within the cardiopulmonary population-i.e. different duration of symptoms than for which the POCT is proven effective. Therefore, it is very important to incorporate a POCT in a tested clinical pathway and to educate GPs on the use of a new POCT. Further research on the effectiveness of using a POCT panel with more than one cardiopulmonary biomarker, may be useful, especially in primary care, where patients sometimes present with vague or a wide range of symptoms (44) .
Conclusion
We conclude that we currently have limited and inconclusive evidence-from prospective and randomized studies with a high risk of bias-that actual GP use of POCT in primary care patients with acute cardiopulmonary symptoms leads to more accurate diagnosis and impacts clinical management. However, some studies show promising results, especially when a POCT is combined with a clinical decision rule, e.g. when GP use of a D-dimer POCT is combined with the Wells clinical decision rule. Further research on the clinical effectiveness of POCT in primary care, preferably in combination with clinical decision rules, is necessary to confirm whether or not POCT could aid GPs in the consultation of patients with acute cardiopulmonary symptoms.
